Speaker Profile
Other, Epigenetic Services Manager, Zymo Research
Biography
Emily Chen is a life sciences professional with over 10 years of experience in NGS service operations. She has led projects across the full workflow—from sample processing to final data delivery—supporting high-throughput NGS applications with a strong focus on quality, efficiency, and collaboration. By optimizing laboratory processes, implementing automation, and streamlining project tracking systems, Emily strives to transform complex and variable biological samples into reliable, actionable data. Her work directly enables genome-, epigenome-, and transcriptome-focused analyses to overcome technical and analytical challenges in molecular diagnostics, improving assay robustness, turnaround time, and data confidence to support accurate decision-making in research and clinical settings.
Talk
Transforming Molecular Diagnostics Through Improved Sample Collection
We will demonstrate how a novel needle biopsy collection device significantly improves nucleic acid yield, integrity, and sequencing performance in molecular diagnostics applications. By connecting biopsy practices to downstream NGS quality metrics, we highlight sample collection as a foundational—and frequently underestimated—determinant of MolDx workflow success.
Clinical Dx Showcase:
Zymo Research
Zymo Research, a privately owned biotech company founded in 1994, is a global leader in molecular tools for life sciences. Driven by the principle "The Beauty of Science is to Make Things Simple," Zymo is dedicated to developing innovative solutions that address complex scientific challenges.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 Data Applications in Clinical Diagnostics Showcase will provide a 15-30 minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
